Man Group plc Has $3.82 Million Position in Janux Therapeutics, Inc. $JANX

Man Group plc cut its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX) by 27.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 248,801 shares of the company’s stock after selling 94,185 shares during the period. Man Group plc owned 0.41% of Janux Therapeutics worth $3,822,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the business. California State Teachers Retirement System grew its holdings in Janux Therapeutics by 1.1% in the 2nd quarter. California State Teachers Retirement System now owns 37,139 shares of the company’s stock valued at $858,000 after buying an additional 404 shares during the last quarter. Versant Capital Management Inc grew its stake in shares of Janux Therapeutics by 42.8% in the second quarter. Versant Capital Management Inc now owns 2,615 shares of the company’s stock worth $40,000 after acquiring an additional 784 shares during the last quarter. Nuveen LLC grew its stake in shares of Janux Therapeutics by 0.8% in the fourth quarter. Nuveen LLC now owns 96,416 shares of the company’s stock worth $1,331,000 after acquiring an additional 787 shares during the last quarter. ProShare Advisors LLC increased its position in Janux Therapeutics by 18.3% during the fourth quarter. ProShare Advisors LLC now owns 10,495 shares of the company’s stock worth $145,000 after acquiring an additional 1,621 shares during the period. Finally, Quantinno Capital Management LP raised its stake in Janux Therapeutics by 7.6% during the 1st quarter. Quantinno Capital Management LP now owns 26,064 shares of the company’s stock valued at $362,000 after purchasing an additional 1,846 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Analyst Upgrades and Downgrades

JANX has been the subject of a number of research reports. Wedbush reduced their price target on shares of Janux Therapeutics from $45.00 to $36.00 and set an “outperform” rating for the company in a report on Friday, May 8th. Piper Sandler lowered their price target on Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Janux Therapeutics in a report on Monday, July 20th. Stifel Nicolaus set a $35.00 price objective on Janux Therapeutics in a research report on Friday, August 7th. Finally, Evercore set a $22.00 price objective on Janux Therapeutics in a report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $36.46.

Insider Buying and Selling at Janux Therapeutics

In other news, insider Janeen Noel Doyle sold 4,059 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $14.03, for a total value of $56,947.77. Following the completion of the transaction, the insider directly owned 75,941 shares of the company’s stock, valued at approximately $1,065,452.23. This represents a 5.07% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 7.90% of the company’s stock.

Janux Therapeutics Stock Performance

NASDAQ:JANX opened at $18.03 on Monday. The company has a 50-day moving average of $16.12 and a 200-day moving average of $14.82. Janux Therapeutics, Inc. has a 52 week low of $12.12 and a 52 week high of $35.34. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of -10.99 and a beta of 2.50.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Thursday, August 6th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.10). The company had revenue of $10.27 million for the quarter, compared to analyst estimates of $19.07 million. Sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.76 EPS for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.